Novartis’ Promacta approved by FDA for first-line treatment of severe aplastic anemia
The U.S. Food and Drug Administration (FDA) has granted an expanded indication for Novartis’ Promacta (eltrombopag), approving it for use in the first-line treatment of ... Read More
US biopharma company Endocyte to be acquired by Novartis for $2.1bn
Novartis acquisition of Endocyte : US biopharma company Endocyte has agreed to be acquired by Swiss pharma company Novartis in a deal worth around $2.1 ... Read More
Novartis to expand radiopharmaceuticals portfolio with $2.1bn Endocyte acquisition
Swiss pharmaceutical company Novartis has announced a strategic acquisition of the US-based biopharma firm Endocyte for approximately $2.1 billion. This move aims to bolster Novartis’s ... Read More
EC approves Novartis’ skin cancer therapy combo Tafinlar and Mekinist for melanoma
In a significant development for melanoma treatment, the European Commission (EC) has granted Novartis approval for its combination therapy of Tafinlar (dabrafenib) and Mekinist (trametinib). ... Read More